Physician profile
Sandra Thomas
NPI 1003161183
$1,323.03
in general payments reported to CMS, 2019-2025
25 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $245 · 2023: $282 · 2024: $137 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $300 · Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $299.93 |
| Food and Beverage | $299.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $231.23 | 2021-2023 | Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $193.76 | 2021-2023 | Imbruvica, Epkinly |
| Dova Pharmaceuticals | $124.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $115.97 | 2021-2024 | |
| Daiichi Sankyo INC. | $77.99 | 2025 | Enhertu |
| Seagen INC. | $54.26 | 2021 | |
| Amgen INC. | $51.82 | 2021-2022 | |
| Janssen Biotech, INC. | $49.99 | 2024 | Darzalex |
| Astellas Pharma US INC | $49.47 | 2021 | |
| Genzyme Corporation | $42.99 | 2021-2022 | |
| Gilead Sciences, INC. | $32.67 | 2022 | |
| Tersera Therapeutics LLC | $29.38 | 2025 | Quzyttir |
| Csl Behring | $28.55 | 2025 | Hizentra |
| Puma Biotechnology, INC. | $27.43 | 2022 | |
| Abbvie INC. | $24.99 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $23.55 | 2023 | Vonjo |
| Bayer Healthcare Pharmaceuticals INC. | $21.54 | 2021 | |
| Merck Sharp & Dohme LLC | $20.14 | 2023 | Keytruda |
| Myovant Sciences INC. | $20.00 | 2021 | |
| Dexcom, INC. | $19.99 | 2025 | Dexcom G6 Transmitter |
| Celgene Corporation | $18.40 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.36 | 2024 | Terlivaz |
| Coherus Oncology, INC. | $17.44 | 2022 | |
| Octapharma USA, INC. | $16.47 | 2021 | |
| Acrotech Biopharma INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.